XML 271 R214.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other revenue (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
 [2]
Dec. 31, 2022
 [2]
Disclosure of information about major customers and credit risk [line items]      
Other revenues € 3,205 € 3,801 [1] € 2,910 [1]
Disclosure of other revenue [Table]
(€ million)
2024
2023(a)
2022(a)
VaxServe sales of non-Sanofi products
1,959
2,167
1,567
COVID-19 vaccine related revenues
—
509
257
Intragroup sales from continuing to discontinued operations (b)
163
188
208
Royalties
121
107
103
Other(c)
623
534
399
Total Biopharma Other revenues
2,866
3,505
2,534
Sales / Revenues from Opella products(d)
339
296
376
Total Other revenues
3,205
3,801
2,910
(a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
(b)Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities
within the scope of discontinued operations.
(c)This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties.
(d)Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of
Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan
agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which
will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection
with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales
of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated
worldwide property rights).
    
Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Other revenues € 2,866 3,505 [3] 2,534 [4],[5]
Royalty income 121 107 103
Revenue from COVID-19 vaccine 0 509 257
Revenue from intragroup sales from continuing to discontinued operations [6] 163 188 208
Miscellaneous other revenue [7] 623 534 399
Revenue from VaxServe sales of non-Sanofi products 1,959 2,167 1,567
Opella Business      
Disclosure of information about major customers and credit risk [line items]      
Other revenues [8] € 339 € 296 € 376
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[3] Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[4] (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[5] (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo
transaction (€706 million net of tax).
[6] (b)Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities
within the scope of discontinued operations.
[7] (c)This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties.
[8] (d)Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of
Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan
agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which
will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection
with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales
of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated
worldwide property rights).